Cost, quality of life and outcome measures in ovarian cancer

Fouad Abbas, M. Bilal Sert

Research output: Contribution to journalArticle

Abstract

As research into cancer intensifies and treatments proliferate, life interval gained is no longer a question of simply measuring time. Ovarian cancer patients, especially, have benefited from efforts to develop feasible screening processes and the new treatment modalities for this type of cancer. Within the last decade, medicine has come to realize that survival intervals and cure rates are useless to patients if they cannot retrieve out of the process at least some aspects of their lives before cancer and for as long a period of time as possible. This article focuses on measuring and assessing the effects of treatment in terms of outcome and quality of life from the patient's perspective. Medicine as a science, and being a science, has not been comfortable in taking into account intangibles when assessing its own performance and success rates. However, the roles of caregivers and health providers have been rapidly evolving from that of treating the disease to treating the patient, and often the patient's family, with all that implies.

Original languageEnglish (US)
Pages (from-to)859-867
Number of pages9
JournalAnti-Cancer Drugs
Volume9
Issue number10
StatePublished - 1998

Fingerprint

Ovarian Neoplasms
Quality of Life
Outcome Assessment (Health Care)
Costs and Cost Analysis
Medicine
Neoplasms
Caregivers
Therapeutics
Survival
Health
Research

Keywords

  • Assessment
  • Cost
  • Measure
  • Outcome
  • Ovarian cancer
  • Quality of life

ASJC Scopus subject areas

  • Pharmacology
  • Cancer Research
  • Oncology

Cite this

Abbas, F., & Sert, M. B. (1998). Cost, quality of life and outcome measures in ovarian cancer. Anti-Cancer Drugs, 9(10), 859-867.

Cost, quality of life and outcome measures in ovarian cancer. / Abbas, Fouad; Sert, M. Bilal.

In: Anti-Cancer Drugs, Vol. 9, No. 10, 1998, p. 859-867.

Research output: Contribution to journalArticle

Abbas, F & Sert, MB 1998, 'Cost, quality of life and outcome measures in ovarian cancer', Anti-Cancer Drugs, vol. 9, no. 10, pp. 859-867.
Abbas, Fouad ; Sert, M. Bilal. / Cost, quality of life and outcome measures in ovarian cancer. In: Anti-Cancer Drugs. 1998 ; Vol. 9, No. 10. pp. 859-867.
@article{099cd6bf6225442f824b2eb8f62e4d3c,
title = "Cost, quality of life and outcome measures in ovarian cancer",
abstract = "As research into cancer intensifies and treatments proliferate, life interval gained is no longer a question of simply measuring time. Ovarian cancer patients, especially, have benefited from efforts to develop feasible screening processes and the new treatment modalities for this type of cancer. Within the last decade, medicine has come to realize that survival intervals and cure rates are useless to patients if they cannot retrieve out of the process at least some aspects of their lives before cancer and for as long a period of time as possible. This article focuses on measuring and assessing the effects of treatment in terms of outcome and quality of life from the patient's perspective. Medicine as a science, and being a science, has not been comfortable in taking into account intangibles when assessing its own performance and success rates. However, the roles of caregivers and health providers have been rapidly evolving from that of treating the disease to treating the patient, and often the patient's family, with all that implies.",
keywords = "Assessment, Cost, Measure, Outcome, Ovarian cancer, Quality of life",
author = "Fouad Abbas and Sert, {M. Bilal}",
year = "1998",
language = "English (US)",
volume = "9",
pages = "859--867",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

TY - JOUR

T1 - Cost, quality of life and outcome measures in ovarian cancer

AU - Abbas, Fouad

AU - Sert, M. Bilal

PY - 1998

Y1 - 1998

N2 - As research into cancer intensifies and treatments proliferate, life interval gained is no longer a question of simply measuring time. Ovarian cancer patients, especially, have benefited from efforts to develop feasible screening processes and the new treatment modalities for this type of cancer. Within the last decade, medicine has come to realize that survival intervals and cure rates are useless to patients if they cannot retrieve out of the process at least some aspects of their lives before cancer and for as long a period of time as possible. This article focuses on measuring and assessing the effects of treatment in terms of outcome and quality of life from the patient's perspective. Medicine as a science, and being a science, has not been comfortable in taking into account intangibles when assessing its own performance and success rates. However, the roles of caregivers and health providers have been rapidly evolving from that of treating the disease to treating the patient, and often the patient's family, with all that implies.

AB - As research into cancer intensifies and treatments proliferate, life interval gained is no longer a question of simply measuring time. Ovarian cancer patients, especially, have benefited from efforts to develop feasible screening processes and the new treatment modalities for this type of cancer. Within the last decade, medicine has come to realize that survival intervals and cure rates are useless to patients if they cannot retrieve out of the process at least some aspects of their lives before cancer and for as long a period of time as possible. This article focuses on measuring and assessing the effects of treatment in terms of outcome and quality of life from the patient's perspective. Medicine as a science, and being a science, has not been comfortable in taking into account intangibles when assessing its own performance and success rates. However, the roles of caregivers and health providers have been rapidly evolving from that of treating the disease to treating the patient, and often the patient's family, with all that implies.

KW - Assessment

KW - Cost

KW - Measure

KW - Outcome

KW - Ovarian cancer

KW - Quality of life

UR - http://www.scopus.com/inward/record.url?scp=0032410250&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032410250&partnerID=8YFLogxK

M3 - Article

C2 - 9890697

AN - SCOPUS:0032410250

VL - 9

SP - 859

EP - 867

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 10

ER -